Bashar

Seventy years of dogma. One trial. And now we're rethinking everything. Yeah. This is a big deal. Here's my honest take: The old trials weren't wrong. They were right for their era. BHAT, the Norwegian Timolol Study - these showed real mortality benefit. But that was 1980s cardiology. No primary PCI. No dual antiplatelet. No high-intensity statins. No widespread ACE inhibitors. Beta blockers were doing a lot of heavy lifting because nothing else was. REDUCE-AMI changed the conversation. ~5,600 patients. Preserved EF (≥50%). Randomized to beta blocker vs none. Result: No difference in death or recurrent MI at 3+ years. That's not a marginal finding. That's a null result in a well-powered trial. What I think: The biology still makes sense. Lower heart rate, lower wall stress, anti-arrhythmic effects. That's real physiology. But modern post-MI care is so good now that the incremental benefit of beta blockers - in patients with preserved EF who got timely reperfusion - might genuinely be zero. We're not stopping beta blockers because they were wrong. We're stopping because everything else got better. The nuance matters though: Reduced EF? Still give them. That evidence holds. Heart failure? Absolutely. Carvedilol, metoprolol succinate, bisoprolol - those trials are solid. Preserved EF, good reperfusion, no arrhythmias? That's where the question lives now. The uncomfortable truth: Medicine holds onto things too long sometimes. We get attached to interventions that "make sense" even when the data softens. Beta blockers post-MI became reflex, not reasoning. REDUCE-AMI forced us to reason again. My position: I think the shift is appropriate for the right patients. But "stop all beta blockers post-MI" isn't the message. It's "stop automatic beta blockers in preserved EF patients who had modern reperfusion therapy." That's narrower. And correct. The harder question: How many other "automatic" things are we doing that made sense in 1985 but don't anymore? That's what keeps cardiologists up at night.